Form 4: United Therapeutics COO Sells Shares After Option Exercise
Insider Transaction Report
United Therapeutics' President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.
Summary
- Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock on December 15, 2025.
- Benkowitz exercised stock options to acquire a total of 22,500 shares: 14,625 shares at an exercise price of $117.76 per share and 7,875 shares at an exercise price of $146.03 per share.
- Concurrently, he sold a total of 22,500 shares of common stock (derived from the option exercises) at weighted average prices ranging from approximately $490.65 to $500.40 per share.
- An additional 2,648 shares of common stock were disposed of directly.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
- The shares involved in the option exercises and sales were held indirectly through trusts where Benkowitz and/or his family members are beneficiaries.
Sentiment
Score: 5
Explanation: The transactions are routine insider sales executed under a pre-established 10b5-1 plan, which typically does not convey strong positive or negative sentiment regarding the company's future prospects. The insider profited significantly, reflecting past stock performance.
Positives
- The insider realized significant gains by exercising stock options at substantially lower prices ($117.76 and $146.03) and selling the shares at much higher market prices (around $490-$500), reflecting the value appreciation of the company's stock.
Negatives
- The sale of a substantial number of shares by a key executive, even if pre-planned, could be interpreted by some investors as a reduction in insider conviction.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Shares were held in a trust (Trust 2) beneficially owned by the reporting person, where he is a beneficiary and he and his spouse are co-trustees with shared investment and voting power.
- Shares were held in a trust (Trust 13) beneficially owned by the reporting person, where his family members are beneficiaries, and he has sole investment and voting power.
Stakeholder Impact
- Shareholders: Minor impact, as these are routine, pre-planned insider sales for diversification or liquidity, not typically signaling a change in company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 03/15/2020 | Stock options became exercisable. |
| 06/03/2025 | Rule 10b5-1 trading plan entered into by the reporting person. |
| 12/15/2025 | Date of option exercise and subsequent common stock sale transactions. |
| 12/16/2025 | Date the Form 4 was signed by Power of Attorney. |
| 03/15/2027 | Stock options expiration date. |
Keywords
United Therapeutics, UTHR, Michael Benkowitz, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Share Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.